Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Phase 1

Completed

• Conditions: Refractory or Recurrent Solid Tumors; Non-Rhabdomyosarcoma Soft Tissue Sarcoma; Rhabdomyosarcoma; Ewing Sarcoma
• Interventions: Drug: Eribulin mesilate; Drug: Irinotecan hydrochloride

• Registration Number: NCT03245450
• Lead Sponsor: Eisai Inc.

Brief Summary

The Phase 1 part of the study is conducted to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed/refractory solid tumors (excluding central nervous system \[CNS\] tumors).

The Phase 2 part of the study is conducted to assess the objective response rate (ORR) and duration of response (DOR) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and ewing sarcoma (EWS).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-08-08
• Study First Submitted QC: 2017-08-08
• Study First Posted: 2017-08-10
• Study Start: 2018-03-05
• Primary Completion: 2021-05-17
• Study Completion: 2021-05-17
• Status Verified: 2021-06
• Results First Submitted: 2022-05-16
• Results First Submitted QC: 2022-06-20
• Last Update Submitted: 2022-06-20
• Results First Posted: 2022-06-28
• Last Update Posted: 2022-06-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Phase 1: Participants must be diagnosed with histologically confirmed solid tumors (excluding CNS tumors), which is relapsed or refractory, and for which there are no currently available therapies.

• Phase 2: Participants must be diagnosed with histologically confirmed RMS, NRSTS or EWS which is relapsed or refractory having received at least 1 prior therapy, including primary treatment.

• Phase 1: Participants must have either measurable or evaluable disease as per RECIST 1.1.

• Phase 2: Participants must have measurable disease as per RECIST 1.1.

• Participant's current disease state must be one for which there is no known curative therapy.

• Participant's performance score must be >=50% Karnofsky (for participants >16 years of age) or Lansky (for participants <=16 years of age).Participants who are unable to walk because of paralysis and/or previous surgeries, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

• Participants must have fully recovered from the acute toxic effects of all prior anticancer treatments prior to study drug administration:

  • Must not have received myelosuppressive chemotherapy within 21 days prior to study drug administration (42 days if prior nitrosourea).
  • Must not have received a long-acting growth factor (example, Neulasta) within 14 days or a short-acting growth factor within 7 days.
  • Must not have received an antineoplastic targeted therapy within 14 days.
  • Must not have received immunotherapy, example, tumor vaccines, within 42 days.
  • Must not have received monoclonal antibodies within at least 3 half-lives of the antibody after its last dose.
  • Must not have received radiotherapy (XRT) within 14 days prior to study drug administration (small field) or 42 days for craniospinal XRT, or if >=50% radiation of pelvis.
  • At least 84 days must have elapsed after stem cell infusion prior to study drug administration
  • No evidence of active graft-versus-host disease (GVHD) and at least 100 days must have elapsed after allogeneic bone marrow transplant or stem cell infusion prior to study drug administration

• Participants must have adequate bone marrow function, defined as:

  • Peripheral absolute neutrophil count (ANC) >=1.0*10^9/liter (L).
  • Platelet count >=100*10^9/L (not receiving platelet transfusions within a 7-day period prior to study drug administration).
  • Hemoglobin (Hb) at least 8.0 grams per deciliter (g/dL) at baseline (blood transfusions are allowed during the screening period to correct Hb values <8.0 g/dL).

• Participants must have adequate renal function, defined as:

  • A serum creatinine based on age/gender, derived from the Schwartz formula for estimating glomerular filtration rate (GFR), per protocol-specified criteria.
  • Serum creatinine clearance or GFR >=50 milliliters/minute/1.73 m^2, based on a 12 or 24 hours (h) urine creatinine collection.

• Participants must have adequate liver function, defined as:

  • Bilirubin (sum of conjugated + unconjugated) <=1.5 times the upper limit of normal (ULN) for age.
  • Alkaline phosphatase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3*ULN (in the case of liver metastases <=5*ULN), unless there are bone metastases, in which case liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
  • Serum albumin >=2 g/dL.

• All participants and/or their parents or guardians must sign a written informed consent.

• Participants must be willing to comply with all aspects of the protocol.

Exclusion Criteria

• Females who are breastfeeding or pregnant at Screening or Baseline. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 h before the first dose of study drug.

• Females of childbearing potential who:

  • Do not agree to use a highly effective method of contraception for the entire study period and for 6 months after study drug discontinuation, that is:
  • Total abstinence (if it is their preferred and usual lifestyle)
  • An intrauterine device (IUD) or intrauterine system (IUS)
  • A contraceptive implant
  • An oral contraceptive OR
  • Do not have a vasectomized partner with confirmed azoospermia.

• Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period or for 3 months after study drug discontinuation). No sperm donation is allowed during the study period or for 3 months after study drug discontinuation.

• Concomitant Medications:

  • Participants receiving corticosteroids who have not been on a stable dose for at least 7 days prior to study drug administration.
  • Participants who are currently receiving other anticancer agents.
  • Participants who are receiving cyclosporine, tacrolimus or other agents to prevent GVHD post bone marrow transplant.
  • Participants who are receiving strong cytochrome P450 3A4 (CYP3A4) inhibitors and inducers including traditional herbal medicinal products (example, St. John's Wort).

• Phase 1: Received prior therapy with eribulin mesilate within 6 months prior to study drug administration.

• Phase 2: Received prior therapies with eribulin mesilate or irinotecan hydrochloride (for prior irinotecan hydrochloride, participants can be included if there was no tumor progression during irinotecan therapy).

• Any other malignancy that required treatment (except non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ), within 2 years prior to study drug administration.

• Has hypersensitivity to either study drug or any of the excipients.

• Has a known prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment

• Has >Grade 1 peripheral sensory neuropathy or >Grade 1 peripheral motor neuropathy graded according to the Modified ("Balis") Pediatric Scale of Peripheral Neuropathies.

• Has cardiac pathology, defined as:

  • Participants with known congestive heart failure, symptomatic or Left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QT interval (QTc)>480 milliseconds on at least 2 separate electrocardiograms (ECGs).

• Has CNS disease: Participants with brain or subdural metastases are not eligible unless the metastases are asymptomatic and do not require treatment or have been adequately treated by local therapy and have discontinued the use of corticosteroids for this indication for at least 28 days prior to study drug administration. Participants must be clinically stable. It is not the intention of this protocol to treat participants with active brain metastases.

Note: Screening CNS imaging for participants with a known history of CNS disease is required.

• Have had or are planning to have the following invasive procedures:

  • Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration.
  • Laparoscopic procedure or open biopsy within 7 days prior to study drug administration
  • Central line placement or subcutaneous port placement is not considered major surgery.
  • Core biopsy, including bone marrow biopsy within 2 days prior to study drug administration.
  • Fine needle aspirate within 3 days prior to study drug administration.

• Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV infected participants.

• Has any serious concomitant illness that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments (including active or severe chronic inflammatory bowel disease or bowel obstruction).

• Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Eribulin mesilate plus irinotecan hydrochloride	Eribulin mesilate	In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m\^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m\^2 or 40 mg/m\^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m\^2 or 125 mg/m\^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
Eribulin mesilate plus irinotecan hydrochloride	Irinotecan hydrochloride	In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m\^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m\^2 or 40 mg/m\^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m\^2 or 125 mg/m\^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.

Primary Outcome Measures

Name	Time	Method
Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride	First dose of study drug up to Cycle 1 (Cycle length=21 days)	The RP2D was evaluated based on a review of the outcomes of safety (including dose limiting toxicities \[DLTs\]), tumor assessments, and pharmacokinetic (PK) in Phase 1 by investigators and the study team.
Phase 2: Objective Response Rate (ORR)	From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 4 months	ORR was defined as the percentage of participants achieving best overall response (BOR) of confirmed partial response (PR) or complete response (CR) determined by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeter (mm). PR was at least a 30 percent (%) decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures

Name	Time	Method
Phase 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Eribulin, Irinotecan and Its Active Metabolite SN-38	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)
Phase 1, Total Clearance (CL) of Eribulin and Irinotecan	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)	CL for irinotecan could not be estimated for phase 1:schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 20 mg/m\^2 and phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 40 mg/m\^2 arm because it was not possible to calculate half-life as the slope of the terminal phase of the concentration-time profiles could not be determined.
Phase 1, Volume of Distribution (Vz) of Eribulin and Irinotecan	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)	Vz for irinotecan could not be estimated for phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 20 mg/m\^2 and phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 40 mg/m\^2 arm because it was not possible to calculate half-life as the slope of the terminal phase of the concentration-time profiles could not be determined.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	From first dose of study drug up to approximately 2 years 4 months	A TEAE was defined as an AE that emerged during treatment, having been absent at pretreatment, or reemerged during treatment, having been present at pre-treatment (baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Number of Participants With Serious Adverse Event (SAE)	Up to approximately 2 years and 4 months	SAE was defined as any untoward medical occurrence at any dose if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
Phase 1, Cmax: Maximum Observed Plasma Concentration of Eribulin, Irinotecan and Its Active Metabolite SN-38	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)
Phase 1, T1/2: Half-life of Eribulin, Irinotecan and Its Active Metabolite SN-38	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)	Half-life for irinotecan and metabolite SN-38 could not be estimated for phase 1:schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 20 mg/m\^2 and phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 40 mg/m\^2 arm as the slope of the terminal phase of the concentration-time profiles could not be determined.
Phase 1, AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of Eribulin, Irinotecan and Its Active Metabolite SN-38	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)
Phase 2: Progression Free Survival (PFS)	From the date of first dose to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 2 years 4 months	PFS was defined as the time from date of first dose to the date of disease progression (PD). PFS was assessed based on the investigators' assessments utilizing RECIST 1.1. PD was defined as at least 20% increase or 5 mm increase in the sum of diameters of target lesions recorded since the treatment started or the appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.
Model Predicted Apparent Total Body Clearance (CL) of Eribulin	Cycle 1 Day 1: 0.5-120 hours after eribulin infusion; Cycle 1 Day 8: pre-dose and at the end of the eribulin infusion (cycle length=21 days)	Per the planned PK analysis, PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Eribulin plasma concentration data from this study were pooled from studies (NCT00069264, NCT00069277, NCT00326950, NCT00706095, NCT01000376, NCT01106248, NCT02171260, NCT00413192, NCT01458249, NCT03441360 and NCT01327885), and a population PK model was applied to the pooled dataset. The data presented are the CL parameter estimates, with Measure Type "Number" defining the eribulin PK model. They are population PK model predictions and have been estimated using non-linear mixed effects model.
Phase 1, AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Eribulin, Irinotecan and Its Active Metabolite SN-38	For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)	AUC(0-inf) for irinotecan and metabolite SN-38 could not be estimated for phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 20 mg/m\^2 and phase 1: schedule A, eribulin mesilate 1.4 mg/m\^2 + irinotecan 40 mg/m\^2 arm because it was not possible to calculate half-life as the slope of the terminal phase of the concentration-time profiles could not be determined.
Phase 2: Clinical Benefit Rate (CBR)	From the date of first dose to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 2 years 4 months	CBR was defined as the percentage of participants with BOR of CR, PR, or durable stable disease (SD) based on RECIST 1.1 (durable SD was defined as SD with duration of greater than \[\>\] 11 weeks). CR was defined as disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.
Volume of Distribution Estimates From the Population PK Model for Eribulin	Cycle 1 Day 1: 0.5-120 hours after eribulin infusion; Cycle 1 Day 8: pre-dose and at the end of the eribulin infusion (cycle length=21 days)	Per the planned PK analysis, PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Eribulin plasma concentration data from this study were pooled from studies (NCT00069264, NCT00069277, NCT00326950, NCT00706095, NCT01000376, NCT01106248, NCT02171260, NCT00413192, NCT01458249, NCT03441360 and NCT01327885), and a population PK model was applied to the pooled dataset. Data presented are the volume of distribution of the central compartment (V1), volume of distribution of the first peripheral compartment (V2), and volume of distribution of the second peripheral compartment (V3) parameter estimates with Measure Type "Number" defining the eribulin PK model. They are population PK model predictions and have been estimated using non-linear mixed effects model.

Trial Locations

Locations (39)

Eisai Trial Site 6; 🇩🇪 Essen, Germany

Eisai Trial Site 1; 🇩🇪 Aachen, Nordrhein-Westfalen, Germany

Ospedale Infantile Regina Margherita; 🇮🇹 Torino, Piemonte, Italy

Hospital Infantil Universitario Niño Jesus; 🇪🇸 Madrid, Spain

John Radcliffe Hospital; 🇬🇧 Oxford, Oxfordshire, United Kingdom

Royal Marsden Hospital - Surrey; 🇬🇧 Sutton, Surrey, United Kingdom

Hopitaux de La Timone; 🇫🇷 Marseille, Bouches-du-Rhône, France

University College London; 🇬🇧 London, United Kingdom

Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi; 🇮🇹 Bologna, Emilia-Romagna, Italy

Aghia Sophia' Children's General Hospital of Athens; 🇬🇷 Athens, Attiki, Greece

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu; 🇵🇱 Wrocław, Dolnoslaskie, Poland

Kinderspital Zürich - Eleonorenstiftung; 🇨🇭 Zürich, Switzerland

Eisai Trial Site 4; 🇩🇪 Freiburg, Baden-Württemberg, Germany

AHEPA University General Hospital of Thessaloniki; 🇬🇷 Thessaloníki, Greece

Centre Léon Berard; 🇫🇷 Lyon, Rhône, France

Hospital Universitario Vall d'Hebron - PPDS; 🇪🇸 Barcelona, Cataluña, Spain

Centre Oscar Lambret; 🇫🇷 Lille, Nord, France

Eisai Trial Site 2; 🇩🇪 Frankfurt, Hessen, Germany

Eisai Trial Site 3; 🇩🇪 Berlin, Germany

Eisai Trial Site 5; 🇩🇪 Gottingen, Niedersachsen, Germany

Ospedale Pediatrico Bambino Gesù; 🇮🇹 Roma, Lazio, Italy

Fondazione Policlinico Universitario A Gemelli; 🇮🇹 Roma, Lazio, Italy

Azienda Ospedaliera A Meyer; 🇮🇹 Firenze, Toscana, Italy

Istituto G Gaslini Ospedale Pediatrico IRCCS; 🇮🇹 Genova, Liguria, Italy

Istituto Nazionale Dei Tumori; 🇮🇹 Milan, Italy

Azienda Ospedaliera Di Padova; 🇮🇹 Padova, Veneto, Italy

Instytut Pomnik Centrum Zdrowia Dziecka; 🇵🇱 Warszawa, Mazowieckie, Poland

Hospital Universitario Virgen del Rocio; 🇪🇸 Sevilla, Spain

Hospital Universitario La Paz; 🇪🇸 Madrid, Spain

Addenbrooke's Hospital; 🇬🇧 Cambridge, Cambridgeshire, United Kingdom

Hospital Universitari i Politecnic La Fe de Valencia; 🇪🇸 Valencia, Spain

Southampton General Hospital; 🇬🇧 Southampton, Hampshire, United Kingdom

Alder Hey Childrens Hospital; 🇬🇧 Liverpool, Merseyside, United Kingdom

The Leeds Teaching Hospitals Charitable Foundation - Leeds Childrens Hospital (LCH); 🇬🇧 Leeds, Yorkshire, United Kingdom

Birmingham Children's Hospital; 🇬🇧 Birmingham, West Midlands, United Kingdom

Royal Victoria Infirmary; 🇬🇧 Newcastle, United Kingdom

The Christie NHS Foundation Trust; 🇬🇧 Manchester, United Kingdom

Royal Manchester Childrens Hospital; 🇬🇧 Manchester, United Kingdom

Hospital Sant Joan de Deu; 🇪🇸 Esplugues De Llobregat, Cataluña, Spain